24 Oct 2017,
  • HSI:
    28,305.88 -181.36 (-0.64%)
    HSCI:
    11,491.07 -67.28 (-0.58%)
    HKSPLC25:
    36,328.23 -221.48 (-0.61%)
    HKSPGEM:
    277.06 -0.55 (-0.20%)
  • HSCEI:
    11,491.07 -67.28 (-0.58%)
    HSCCI:
    4,394.17 -1.23 (-0.03%)
    HSFML25:
    9,962.34 -50.63 (-0.51%)
    H-FIN:
    18,492.56 -47.12 (-0.25%)
  • Hang Seng Index
  • 28,305.88

  • -181.36 (-0.64%)
HSCI 11,491.1 -67.3
HKSPLC25 36,328.2 -221.5
HKSPGEM 277.1 -0.6
HSCEI 11,491.1 -67.3
HSCCI 4,394.2 -1.2
HSFML25 9,962.3 -50.6
H-FIN 18,492.6 -47.1
Stay Connected With EQS TodayIR

Modern Dental Group Limited (03600.HK)

Health Care

INTRADAY CHART

more

FINANCIAL REPORTSmore

2017 (IR)
2016 (AR)
2016 (IR)

PRESENTATIONSmore

  • Interim Resul ...
    2016
Modern Dental Group Limited (現代牙科集團有限公司) (“Modern Dental”) is a leading global dental prosthetic device provider with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards and anti-snoring devices. Our success in this industry is rooted in our global proprietary sales and distribution network which we established through a series of strategic acquisitions of our former distributors. Our sales and distribution network provides us with direct access to customers, including dentists, dental clinics, hospitals, distributors and other customers, in key prosthetics markets around the globe, allowing us to promote our products in a targeted manner and better satisfy the needs and preferences of our diverse global customer base. We have 21 points of sale in China and 29 service centers overseas. For the six months ended 30 June, 2015, we had a customer base of over 12,000 customer accounts...
+ More Company Profile
Audit committee

Our Company established an audit committee on November 25, 2015 in compliance with Rule 3.21 of the Listing Rules. Written terms of reference in compliance with paragraph C.3.3 of the CG Code has been adopted. The primary roles of our audit committee include, but are not limited to, (a) making recommendations to our Board on the appointment, reappointment and removal of the external auditor, and approving the remuneration and terms of engagement of the external auditor, and any questions of its resignation or dismissal; (b) monitoring integrity of our financial statements and annual report and accounts, half-year report and, if prepared for publication, quarterly reports, and reviewing significant financial reporting judgments contained in them; and (c) reviewing our financial controls, internal control and risk management systems. Our audit committee consists of three members, namely, Dr. Cheung Wai Bun Charles J.P., Dr. Chan Yue Kwong Michael and Dr. Wong Ho Ching. Dr. Cheung Wai Bun Charles J.P. is the chairman of our audit committee.
 

 
Remuneration committee

Our Company established a remuneration committee on November 25, 2015 in compliance with Rule 3.25 of the Listing Rules. Written terms of reference in compliance with paragraph B.1.2 of the CG Code has been adopted. The primary roles of our remuneration committee include, but are not limited to, (a) making recommendations to our Board on our policy and structure for the remuneration of all of our Directors and senior management personnel and on the establishment of a formal and transparent procedure for developing remuneration policy; (b) reviewing and approving our management’s remuneration proposals with reference to our Board’s corporate goals and objectives; and (c) making recommendations to our Board on the remuneration of non-executive Directors. Our remuneration committee consists of five members, namely, Dr. Wong Ho Ching, Dr. Cheung Wai Man William, Dr. Chan Yue Kwong Michael, Mr. Ngai Chi Ho Alwin, and Ms. Chan Yik Yu. Dr. Wong Ho Ching is the chairman of our remuneration committee.

 
Nomination committee

Our Company established a nomination committee on November 25, 2015 in compliance with paragraph A.5.1 of the CG Code. Written terms of reference in compliance with paragraph A.5.2 of the CG Code has been adopted. The primary roles of our nomination committee include, but are not limited to, (a) reviewing the structure, size and composition (including the skills, knowledge and experience) of our Board at least annually and making recommendations on any proposed changes to our Board to complement our corporate strategy; (b) identifying individuals suitably qualified to become our Board members and selecting or making recommendations to our Board on the selection of individuals nominated for directorships; and (c) assessing the independence of our independent non-executive Directors. Our nomination committee consists of five members, namely, Dr. Chan Yue Kwong Michael, Dr. Cheung Wai Bun Charles J.P., Dr. Cheung Wai Man William, Mr. Ngai Shing Kin and Dr. Chan Ronald Yik Long. Dr. Chan Yue Kwong Michael is the chairman of our nomination committee.

 
Director Nomination Procedures
 
The Board of Directors – Corporate Governance Functions
 
List of Directors and their Roles and Functions
 
Disclosure Policy
 
Schedule of Matters Specially Reserved For the Board of Directors and Functions Delegated to the Management of the Company
 
Policy for Employees to Raise Concerns About Possible Improprieties
 

UPCOMING EVENT

S M T W T F S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31        

COMPANY INFORMATION

Listed Date 30 Jan 2015

Address Units 1701-1702,
1708-1712 & 1715-1716,
17/F, CEO Tower,
77 Wing Hong Street,
Cheung Sha Wan, Kowloon, Hong Kong

Telephone 3766 0777

Facsimile 3766 0700

Email info@moderndentallab.com

No. of Click Rate

67727